Table 1.
Ultrasonic techniques for cancer-targeted drug delivery system.
| Even | Model | Cancer Types | Delivery Vehicles |
Ultrasonic Frequency | Effect | Ref. |
|---|---|---|---|---|---|---|
| Biopsy | Patients | Breast cancer | Microbubbles | 4.5 to 15 MHz | Enhanced preoperative axillary staging | [31] |
| In vitro/in vivo | AsPC1/transgenic pancreatic cancer mouse | Pancreatic ductal adenocarcinoma | Microbubbles | 21 MHz | Increased Thy1 expression in PDAC | [32] |
| In vivo | MDA-MB-231, MCF-7, MCF-12A | Breast cancer | Microbubbles | 5 to 7.5 MHz | Enhanced drug response | [33] |
| In vitro/in vivo | PC-3 | Prostate cancer | Microbubbles | 1 MHz | Enhanced Efficacy of Photodynamic Therapy | [34] |
| In vitro/in vivo | Bel-7402 Bel-7402, SKOV-3, MB-231 |
Cervical, ovarian, and breast cancer | Microbubbles | 0.8 to 3.5 MHz | Enhanced and synergistic chemotherapy |
[35] |
| In vitro/in vivo | MCF-7 | Breast cancer | Microbubbles | 2 to 10 MHz | Enhancing therapeutic efficacy | [36] |
| In vitro/in vivo | HT-29 | Colorectal cancer | Microbubbles | 1 to 12 MHz | Overcomes Multidrug Resistance | [37] |
| In vivo | PC-3, LNCaP | Prostate cancer | Microbubbles | 5 to 10 MHz | Enhances the detection of tumor cells | [38] |
| In vitro/in vivo | Walker-256 BC | Breast cancer | Microbubbles | 1.5 to 7.5 MHz | Inhibiting the tumor growth | [39] |
| In vitro | LS174T, CT26 | Colon cancer | Microbubbles | 3.2 MHz | Enhances the monitoring of the therapy | [40] |
| In vitro | MDA-MB-231 | Breast cancer | Microbubbles | 9 MHz | Optimization of the target condition | [41] |
| In vitro | HUVECs | Endothelial cells | Microbubbles | 0.4 to 8.5 MHz | Enhancing the efficiency of labeling | [42] |
| In vitro/in vivo | CT26 | Colon cancer | Microbubbles | 6.5 MHz | Induce photothermal therapy activity | [43] |
| In vitro | PC-3, LNCaP | Prostate cancer | Microbubbles | 5 to 12 MHz | Enhancing the efficiency of labeling | [44] |
| In vitro/in vivo | MDA-MB-231 | Triple-negative breast cancer | Microbubbles | 1.5 to 12.5 MHz | Enhancing the efficiency of labeling | [45] |
| In vivo | MDA-MB-231 | Breast cancer | Microbubbles | 32 MHz | Enhancing the efficiency of radiation therapy | [46] |
| In vivo | VX2 | Liver cancer | Microbubbles | 3 to 9 MHz | Improved the antitumor effect | [47] |
| In vitro/in vivo | OVCAR-3, 4T1 | Breast cancer, ovarian cancer | Microbubbles | 6 to 10 MHz | Enhancing the delivery of drugs | [48] |
| In vitro | MOLM-13 | Leukemia | Microbubbles | 1.108 MHz | Enhanced the therapeutic effectiveness of treatment | [49] |
| In vitro/in vivo | Bel-7402 | Liver cancer | Microbubbles | 1 MHz | Improved diagnostic accuracy and synergistic treatment | [50] |
| In vitro/in vivo | TRAMP | Prostate cancer | Microbubbles | 7 MHz | Improved the efficiency of diagnosis | [51] |
| In vivo | VX2 | Liver cancer | Microbubbles | 1 MHz | Enhanced the response to treatment | [52] |
| In vivo | MDA-MB-231 | Breast cancer | Microbubbles | 8 MHz | Enhanced the efficacy of therapy | [53] |
| In vitro/in vivo | SVR | Cholangiocarcinoma | Microbubbles | 40 MHz | Enhancing diagnostic and therapeutic capabilities | [54] |
| In vitro/in vivo | KHT-C | Fibrosarcoma | Microbubbles | 4 to 5.2 MHz | Improved the efficiency of diagnosis | [55] |
| In vitro/in vivo | MDA-MB-231 | Breast cancer | Microbubbles | 7 MHz | Improved the efficiency of diagnosis | [56] |
| In vivo | Spontaneous tumor mice | Liver cancer | Microbubbles | 1.6 MHz | Improved the efficiency of diagnosis | [57] |
| In vitro/in vivo | MC38 | Colon cancer | Microbubbles | 4 MHz | Enhanced immune response | [58] |
| In vitro | PaCa-2 | Pancreatic cancer | Microbubbles | 2 MHz | Enhanced the efficacy of therapy | [59] |
| In vivo | MDA-MB-231 | Breast cancer | Microbubbles | 20 MHz | Improve the efficiency of diagnosis | [60] |
| In vitro/in vivo | VX2 | Liver cancer | Microbubbles | 3.5 MHz | Enhanced drug delivery and therapeutic effect | [61] |
| In vivo | Tumorigenesis induced by diethylnitrosamine | Liver cancer | Microbubbles | 21 MHz | Enhanced the therapeutic effect | [62] |
| In vivo | RT112 | Bladder cancer | Microbubbles | 8 MHz | Enhanced the therapeutic effect | [63] |
| In vitro/in vivo | U14 | Cervical carcinoma | Microbubbles | 18 MHz | Enhanced the therapeutic effect | [64] |
| In vivo | VX2 | Liver cancer | Microbubbles | 9 MHz | Improved the efficiency of diagnosis | [65] |
| In vivo | PC-3 | Prostate cancer | Microbubbles | 25 MHz | Enhanced the therapeutic effect | [66] |
| In vivo | PANC-1 | Pancreatic cancer | Microbubbles | 4 MHz | Enhanced the therapeutic effect | [67] |
| Biopsy | Patients | Breast cancer | Microbubbles | 6 to 15 MHz | Improved the efficiency of diagnosis | [68] |
| In vitro/in vivo | SCC-7 | Mouse squamous cell carcinoma | Microbubbles | 1 MHz | Enhanced the therapeutic effect | [69] |
| In vivo | MDA-MB-231 | Breast cancer | Microbubbles | 21 MHz | Improved the efficiency of diagnosis | [70] |
| In vitro/in vivo | MDA-MB-231 | Breast cancer | Microbubbles | 25 MHz | Enhanced the therapeutic effectiveness of treatment | [71] |
| In vivo | PC-3 | Prostate cancer | Micro/nanobubbles | 18 MHz | Improved the efficiency of diagnosis | [72] |
| In vitro/in vivo | C6 | Glioma | Micro/nanobubbles | 1 to 10 MHz | Antitumor activity | [73] |
| In vitro/in vivo | MDA-MB-468 | Breast cancer | Microbubbles/liposomes | 1 MHz | Improved the delivery of materials | [74] |
| In vitro/in vivo | Cal-27, OECM-1 | Oral cancer | Nanobubbles | 7 MHz | Promoted the release of reactive oxygen species (ROS) | [75] |
| In vitro | CT26 | Colon cancer | Nanobubbles | 13 to 24 MHz | Enhanced the therapeutic effect | [76] |
| In vitro/in vivo | SKBR3 | Breast cancer | Nanobubbles | 22 MHz | Enhanced the targeting precision | [77] |
| In vitro/in vivo | MDA-MB-231 | Breast cancer | Nanobubbles | 3 to 9 MHz | Enhanced the precision and accuracy of targeting and diagnosis | [78] |
| In vitro/in vivo | 4T1 | Breast cancer | Nanobubbles | 1 MHz | Enhanced drug delivery and therapeutic effect | [79] |
| In vitro/in vivo | U87, MDA-MB-231 | Glioblastoma, breast cancer | Nanobubbles | 7.5 MHz | Improved diagnostic accuracy and synergistic treatment | [80] |
| In vitro/in vivo | OVCAR-3, 4T1 | Breast cancer, ovarian cancer | Nanobubbles | 12 MHz | Enhancing the delivery of drugs | [48] |
| In vitro/in vivo | MCF-7, MDA-MB-468 | Breast cancer | Nanobubbles | 18 to 21 MHz | Enhancing diagnostic and therapeutic capabilities | [81] |
| In vitro/in vivo | PC-3 | Prostate cancer | Nanobubbles | 12 MHz | Enhancing the sensitivity of diagnosis | [82] |
| In vitro/in vivo | LNCaP, C4-2, and PC-3 | Prostate cancer | Nanobubbles | 13 to 24 MHz | Improved the efficiency of diagnosis | [83] |
| In vitro/in vivo | MDA-MB-231, MDA-MB-468 | Breast cancer | Nanobubbles | 13 to 24 MHz | Enhanced drug delivery and therapeutic effect | [84] |
| In vivo | PC-3 | Prostate cancer | Nanobubbles | 18 MHz | Improved diagnostic accuracy and synergistic treatment | [85] |
| In vitro/in vivo | 4T1 | Breast cancer | Nanobubbles | 7.5 MHz | Enhanced drug delivery and therapeutic effect | [86] |
| In vivo | LN-229 | Glioblastoma | Nanobubbles | 12 MHz | Improved the efficiency of diagnosis | [87] |
| In vitro/in vivo | MDA-MB-231 | Breast cancer | Nanobubbles | 18 to 38 MHz | Enhanced drug delivery and diagnosis | [88] |
| In vitro/in vivo | Mia-Paca2 | Pancreatic cancer | Nanobubbles | 7.5 MHz | Improved diagnostic accuracy and synergistic treatment | [89] |
| In vitro/in vivo | 4T1 | Breast cancer | Nanobubbles | 7.5 MHz | Improved the efficiency of diagnosis | [90] |
| In vitro | MiaPaCa-2, Panc-1, MDA-MB-231, AW-8507 | Pancreatic cancer, breast cancer, head, and neck cancer | Nanobubbles/liposomes | 1 MHz | Improved the efficiency of diagnosis | [91] |
| In vitro/in vivo | MDA-MB-231, B16F10 | Breast cancer, melanoma | Liposomes | 1 to 12 MHz | Improved diagnostic accuracy and synergistic treatment | [92] |
| In vitro | SKOV3, A549 | Ovarian cancer, lung cancer | Liposomes | 5 to 12 MHz | Enhanced drug delivery and therapeutic effect | [93] |
| In vitro/in vivo | MDA-MB-231 | Breast cancer | Liposomes | 1.3 MHz | Enhanced drug delivery and diagnosis | [94] |
| In vitro | NCI-N87 | Gastric cancer | Liposomes | 10 MHz | Enhanced drug delivery and diagnosis | [95] |
| In vivo | 4T1 | Breast cancer | Liposomes | 40 MHz | Improved diagnostic accuracy and synergistic treatment | [96] |
| In vivo | GL261 | Glioma | Liposomes | 1 to 2 MHz | Enhanced drug delivery and therapeutic effect | [97] |